Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Summary

To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 among individuals with Binge Eating Disorder. This is a single-center phase 2a open-label study to assess the safety and feasibility of a single dose of TRP 8802 in subjects with BED. Subjects will undergo screening, preparation therapy sessions, dosing, integration therapy sessions, and follow-up for 12 weeks following the dose of TRP 8802. The total participation in the study will be up to approximately 5 months.

Timeline

Start

2022-03-16

Primary completion

2024-03-07

Completion

2024-06-07

Outcome

Met primary endpoint

release “TRP-8802 demonstrated significant and prolonged improvement in primary endpoints for all five patients” entropyneurodynamics.com ↗

Drugs

Indications